Advances in the Diagnosis of Tuberculosis Infection;Avances en el diagnóstico de la infección tuberculosa

Archivos de Bronconeumologia

Volumn 47, Issue 10, 2011, Pages 521-530

  Arias Guillén, Miguel ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

IGRA conversions; IGRA reversions; Interferon gamma release assays (IGRA); Latent TB infection (LTBI); Quantiferon TB Gold In Tube (QTF GIT); T SPOT.TB; Tuberculin test (PPD); Tuberculosis

Indexed keywords

MYCOBACTERIUM ANTIGEN;

ANTIGEN SPECIFICITY; CHRONIC KIDNEY FAILURE; ENTERITIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; IN VITRO STUDY; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; NONHUMAN; QUANTITATIVE ANALYSIS; REFERENCE VALUE; RHEUMATIC DISEASE; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; TUBERCULIN TEST; TUBERCULOSIS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; INFLAMMATORY BOWEL DISEASE; PREDICTIVE VALUE; PROGNOSIS; READING; SPAIN;

DECISION TREES; HUMANS; TUBERCULOSIS, PULMONARY;

EID: 80053386381     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2011.06.018     Document Type: Short Survey

References (88)

1. World Health Organisation. WHO Report 2008. Global tuberculosis control [consultado 3 Jun 2011]. Disponible en: http://www.who.int/tb/publications/global_report/2008/pdf/fullreport.pdf.
2. Rodríguez E., Villarrubia S., Díaz O., Hernández G., Tello O. Casos de tuberculosis declarados a la Red Nacional de Vigilancia Epidemiológica en 2009. Bol Epidemiol Sem 2010, 18:213-220.
3. Geiter L.J., Gordin F.M., Hersfield E., Horsburgh C.R., Hereb J.A., Jordan T.J., et al. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000, 161:S221-S524.
4. Plan para la prevención y control de la tuberculosis en España. Arch Bronconeumol 2009, 45:139-144. Grupo de Trabajo de Tuberculosis de las Sociedades Científicas.
5. Dunlap N.E., Bass J., Fujiwara P., Hopewell P., Horsburgh C.R., Salfinger R., et al. ATS. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000, 161:1376-1395.
6. González-Martín J., García-García J.M., Anibarro L., Vidal R., Esteban J., Blanquer R., et al. Documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis. Arch Bronconeumol 2010, 46:255-274.
7. Domínguez J., Ruiz-Manzano J. Prueba de la tuberculina: ¿es la hora del cambio?. Arch Bronconeumol 2006, 42:47-48.
8. Food and Drug Administration. QuantiFERON-TB Gold In-Tube - P010033/S011 [consultado 16 Jun 2010]. Disponible en: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/ucm106548.htm.
9. Oxford Immunotec Limited. T-SPOT.TB [U.K. package insert] [consultado 16 Jun 2010]. Disponible en: http://www.oxfordimmunotec.com/96-UK.
10. Menzies D., Pai M., Comstock G. Meta-analysis: New test for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007, 146:340-354.
11. Lalvani A., Pathan A.A., Durkan H., Wilkinson K.A., Whelan A., Deeks J.J., et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001, 357:2017-2021.
12. Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet; 2003;361:1168-73.
13. Domínguez J, Ruiz-Manzano J, De Souza-Galvao M, Latorre I, Milà C, Blanco S, et al. Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis. Clin Vaccine Immunol; 2008;15:168-71.
14. Soysal A, Millington KA, Bakir M, Dosanjh D, Aslan Y, Deeks JJ, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet. 2005;366:1443-51.
15. Connell T.G., Ritz N., Paxton G.A., Buttery J.P., Curtis N., Ranganathan S.C. A three-way comparison of tuberculin skin testing, QuantiFERON-TB Gold and T-SPOT.TB in children. PLoS ONE 2008, 3:e2624.
16. Diel R., Loddenkemper R., Meywald-Walter K., Gottschalk R., Nienhaus A. Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold in tube assay, and T-SPOT.TB test in contact investigations for tuberculosis. Chest 2009, 135:1010-1018.
17. Nicol M.P., Davies M.A., Wood K., Hatheril M., Workman L., Hawkridge A., et al. Comparison of T-SPOT.TB assay and tuberculin skin test for the evaluation of young children at high risk for tuberculosis in a community setting. Pediatrics 2009, 123:38-43.
18. Nakaoka H., Lawson L., Squire S.B., Coulter B., Ravn P., Brock I., et al. Risk for tuberculosis among children. Emerg Infect Dis 2006, 12:1383-1388.
19. Chun J.K., Kim C.K., Kim H.S., Jung J.Y., Lee T.J., Kim K.H., et al. The role of a whole blood interferon-gamma assay for the detection of latent tuberculosis infection in Bacille Calmette-Guerin vaccinated children. Diagn Microbiol Infect Dis 2008, 62:389-394.
20. Okada K., Mao T.E., Mori T., Miura T., Sugiyama T., Mitarai S., et al. Performance of an interferon-gamma release assay for diagnosing latent tuberculosis infection in children. Epidemiol Infect 2008, 136:1179-1187.
21. Connell T.G., Curtis N., Ranganathan S.C., Buttery J.P. Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax 2006, 61:616-620.
22. Hill P.C., Brookes R.H., Adetifa I.M., Fox A., Jackson-Sillah D., Lugos M.D., et al. Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics 2006, 117:1542-1548.
23. Stephan C., Wolf T., Goetsch U., Bellinguer O., Nisius G., Oremek G., et al. Comparing QuantiFERON tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. AIDS 2008, 22:2471-2479.
24. Jones S., De Gijsel D., Wallach F.R., Gurtman A.C., Shi Q., Sacks H. Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV infected individuals. Int J Tuberc Lung Dis 2007, 11:1190-1195.
25. Rangaka M.X., Diwakar L., Seldon R., Van Cutsem G., Meintjes G.A., Morroni C., et al. Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV infected Africans. Clin Infect Dis 2007, 44:1639-1646.
26. Harboe M., Oettinger T., Wiker H.G., Rosenkrands I., Andersen P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 1996, 64:16-22.
27. Houk V.N., Baker J.H., Sorensen K., Kent D.C. The epidemiology of tuberculosis infection in a closed environment. Arch Environ Health 1968, 16:26-35.
28. Lalvani A., Pathan A.A., McShane H., Wilkinson R.J., Latif M., Conlon C.P., et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001, 163:824-828.
29. Dheda K., Lalvani A., Miller R.F., Scott G., Booth H., Johnson M.A., et al. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 2005, 19:2038-2041.
30. Clark S.A., Martin S.L., Pozniak A., Steel A., Ward B., Dunning J., et al. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 2007, 150:238-244.
31. Raby E., Moyo M., Devendra A., Banda J., De Haas P., Ayles H., et al. The effects of HIV on the sensitivity of a whole blood IFN-g release assay in Zambian adults with active tuberculosis. PLoS ONE 2008, 3:e2489.
32. Zabana Y., Domènech E., San Román A.L., Beltrán B., Cabriada J.L., Saro C., et al. MA. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis 2008, 14:1387-1391.
33. Lalvani A., Millington K.A. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008, 8:147-152.
34. Theis V.S., Rhodes J.M. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008, 27:19-30. Epub 2007 Oct 16.
35. Obrador A., López San Román P., Muñoz J., Fortún J., Gassull M.A. Guía de consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Gastroenterol Hepatol 2003, 26:29-33. Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU).
36. López-San Román A., Obrador A., Fortún J., Muñoz P., Gassull M.A. Recommendations on tuberculosis and treatment of inflammatory bowel disease with infliximab. Gastroenterol Hepatol 2006, 29:81-84. Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU).
37. Sellam J., Hamdi H., Roy C., Baron G., Lemann M., Puéchal X., et al. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007, 66:1610-1615.
38. Bartalesi F., Vicidomini S., Goletti D., Fiorelli C., Fiori G., Melchiorre D., et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009, 33:586-593.
39. Martin J., Walsh C., Gibbs A., Mc Donell T., Fearon U., Keane J., et al. Comparison of interferon-gamma-release assays and conventional screening tests before tumour necrosis factor-alpha blockade in patients with inflammatory arthritis. Ann Rheum Dis 2009, 69:181-185.
40. NICE clinical guideline 117. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control Ordering information. Issue date: March 2011 [consultado 3 Jun 2011]. Disponible en: http://www.nice.org.uk/guidance/CG117.
41. Ponce de Leon D., Acevedo-Vasquez E., Alvizuri S., Cucho M., Alfaro J., Perich R., et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008, 35:776-781.
42. Shankar M.S., Aravindan A.N., Sohal P.M., Kohli H.S., Sud K., Gupta K., et al. The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: Tuberculin test and the risk of post-transplant tuberculosis. Nephrol Dial Transplant 2005, 20:2720-2724.
43. Poduval R.D., Hammes M.D. Tuberculosis screening in dialysis patients: Is the tuberculin test effective?. Clin Nephrol 2003, 59:436-440.
44. Fang H.C., Chou K.J., Chen C.L., Lee P.T., Chiou Y.H., Hung S.Y., et al. Tuberculin skin test and anergy in dialysis patients of a tuberculosis-endemic area. Nephron 2002, 91:682-687.
45. Smirnoff M., Patt C., Seckler B., Adler J.J. Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 1998, 113:25-27.
46. Chia S., Karim M., Elwood R.K., FitzGerald J.M. Risk of tuberculosis in dialysis patients: A population-based study. Int J Tuberc Lung Dis 1998, 2:989-991.
47. Chou K.J., Fang H.C., Bai K.J., Hwang S.J., Yang W.C., Chung H.M. Tuberculosis in maintenance dialysis patients. Nephron 2001, 88:138-143.
48. Moore D.A., Lightstone L., Javid B., Friedland J.S. High rates of tuberculosis in endstage renal failure: The impact of international migration. Emerg Infect Dis 2002, 8:77-78.
49. Hickstein L., McPherson C., Kwalick D., DeFriez V., Todd R., Ijaz K., et al. Tuberculosis transmission in a renal dialysis center-Nevada, 2003. Morb Mortal Wkly Rep 2004, 53:873-875.
50. Sester U., Junker H., Hodapp T., Schütz A., Thiele B., Meyerhans A., et al. Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant 2006, 21:3258-3262.
51. Wauters A., Peetermans W.E., Van der Brande P., De Moor B., Evenepoel P., keuleers H., et al. The value of tuberculin skin testing in hemodialysis patients. Nephrol Dial Transplant 2004, 19:433-438.
52. Descamps-Latscha B., Chatenoud L. T cells and B cells in chronic renal failure. Semin Nephrol 1996, 16:183-191.
53. González-Gutiérrez M., De Francisco A.L.M., Sanz S., Ruiz J.C., Prieto M., García Fuentes M., et al. Interleukin-2 deficit in hemodialysis patients. Role of prostaglandins. Renal Failure 1992, 14:563-569.
54. Fernández-Fresnedo G., Ramos M.A., González-Pardo M.C., De Francisco A.L., Lopez-Hoyos M., Arias M., et al. B lymphopenia in uraemia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrol Dial Transplant 2000, 15:502-510.
55. Passalent L., Khan K., Richardson R., Wang J., Dedier H., Gardam M. Detecting latent tuberculosis infection in hemodialysis patients: A head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol 2007, 2:68-73.
56. Palomar R., Arias-Guillén M., Robledo C., Agüero J., Rodriguez C., Molinos L., et al. Detección de la infección tuberculosa latente en pacientes en diálisis peritoneal: nuevos métodos. Nefrología 2011, 31.
57. Vynnycky E., Fine P.E. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000, 152:247-263.
58. Diel R., Loddenkemper R., Meywald-Walter K., Niemann S., Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008, 177:1164-1170.
59. Stout J.E., Menzies D. Predicting tuberculosis: does the IGRA tell the tale?. Am J Respir Crit Care Med 2008, 177:1055-1057.
60. Kik S.V., Franken W.P., Mensen M., Cobelens F.G., kamphorst M., Arend S.M., et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010, 35:1346-1353.
61. Adetifa I.M., Lugos M.D., Hammond A., Jeffries D., Donkor S., Adeqbola R.A., et al. Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia. BMC Infect Dis 2007, 7:122.
62. Dominguez J., Ruiz-Manzano J., De Souza-Galvão M., Latorre I., Milà C., Blanco S., et al. Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis. Clin Vaccine Immunol 2008, 15:168-171.
63. Arend S.M., Thijsen S.F., Leyten E.M., Bouwman J.J., Franken W.P., Koster B.F., et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 2007, 175:618-627.
64. Diel R., Loddenkemper R., Meywald-Walter K., Gottschalk R., Nienhaus A. Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold in Tube assay, and T-SPOT.TB test in contact investigations for tuberculosis. Chest 2009, 135:1010-1018.
65. Tsiouris S.J., Austin J., Toro P., Coetzee D., Weyer K., Stein Z., et al. Results of a tuberculosis-specific IFN-gamma assay in children at high risk for tuberculosis infection. Int J Tuberc Lung Dis 2006, 10:939-941.
66. Janssens J., Roux-Lombard P., Perneger T., Metzqer M., Vivien R., Rochat T. Contribution of a IFN-gamma assay in contact tracing for tuberculosis in a low-incidence, high immigration area. Swiss Med Wkly 2008, 138:585-593.
67. Hill P.C., Brookes R.H., Fox A., Jackson-Sillah D., Jeffries D.J., Lugos M.D., et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 2007, 4:e192.
68. Pai M., Joshi R., Dogra S., Mendiratta D.K., Narang P., Kalantri S., et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 2006, 174:349-355.
69. Ewer K., Millington K.A., Deeks J.J., Alvarez L., Bryant G., Lalvani A., et al. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006, 174:831-839.
70. Hill P.C., Jeffries D.J., Brookes R.H., Fox A., Jackson-Sillah D., Lugos M.D., et al. Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts. PLoS ONE 2007, 2:e183.
71. Corbett E.L., Kathryn C., Millington K.A., Ewer K., Cheung Y.Y. Tuberculosis infection in African nursing students: Tuberculin skin test compared to ELISPOT conversion rates. Int J Tuberc Lung Dis 2006, 10:S231.
72. Doherty T.M., Demissie A., Olobo J., Wolday D., Britton S., Equale T., et al. Immune responses to the Mycobacterium tuberculosis specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002, 40:704-706.
73. Geiter L.J., Gordin F.M., Hersfield E., Horsburgh C.R., Hereb J.A., Jordan T.J., et al. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000, 161:S221-S247.
74. Andersen P., Doherty T.M., Pai M., Weldingh K. The prognosis of latent tuberculosis: Can disease be predicted?. Trends Mol Med 2007, 13:175-182.
75. Booth P.H., Miller R.F., Scott G., Badri M., Huggett J.F., Rook G., et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulmonary Medicine 2010, 10:7.
76. Diel R., Nienhaus A., Lange C., Schaberg T. Cost-optimization of screening for latent tuberculosis in close contacts. Eur Respir J 2006, 28:35-44.
77. Wrighton-Smith P., Zellweger J.P. Direct cost of three models for the screening of latent tuberculosis infection. EurRespir J 2006, 28:45-50.
78. Dewan P.K., Grinsdale J., Liska S., Wong E., Fallstad R., Kawamura L.M. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infectious Diseases 2006, 6:47.
79. Pai M., Zwerling A., Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149:177-184. Epub 2008 Jun 30.
80. Arend S.M., Thijsen S.F., Leyten E.M., Bouwman J.J., Franken W.P., Koster B.F., et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 2007, 175:618-627.
81. Ferrara G., Losi M., D'Amico R., Roversi P., Piro R., Meacci M., et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006, 367:1328-1334.
82. Lee J.Y., Choi H.J., Park I.N., Hong S.B., Oh Y.M., Lim C.M., et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006, 28:24-30.
83. Beffa P., Zellweger A., Janssens J.P., Wrighton-Smith P., Zellweger J.P. Indeterminate test results of T-SPOT.TB performed under routine field conditions. Eur Respir J 2008, 31:842-846.
84. Bakir M., Millington K.A., Soysal A., Deeks J.J., Efee S., Aslan Y., et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med 2008, 149:777-787.
85. Hill P.C., Jackson-Sillah D.J., Fox A., Brookes R.H., De Jong B.C., Lugos M.D., et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS ONE 2008, 3:e1379.
86. Doherty T.M., Demissie A., Olobo J., Wolday D., Britton S., Equale T., et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002, 40:704-706.
87. Aichelburg M.C., Rieger A., Breitenecker F., Pfistershammer K., Tittes J., Eltz S., et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009, 48:954-962.
88. Verver S., Warren R.M., Munch Z., Richardson M., Van Der Spuy G.D., Borgdorff M.W., et al. Proportion of tuberculosis transmission that takes place in households in a high-incidence area. Lancet 2004, 363:212-214.